Exosome-Mediated mRNA Delivery for SARS-CoV-2 Vaccination—Preclinical Advances Published in PrePrint by Capricor Therapeutics; Data Demonstrates Enhanced Expression & Lower Toxicity Compared to Lipid Nanoparticles; Webcast Thursday

On March 9, 2021, Capricor Therapeutics, Inc. (NASDAQ: CAPR) (https://capricor.com/), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, in collaboration with researchers, announced that new advances from its positive preclinical study for a multi-valent exosome-based mRNA vaccine for COVID-19 have been posted on the bioRxiv preprint server (https://www.biorxiv.org/content/10.1101/2020.11.06.371419v2) and the article been submitted for publication. The title of the preprint is “Exosome-Mediated mRNA Delivery for SARS-CoV-2 Vaccination.” “Capricor previously demonstrated that our exosome-based multivalent RNA delivery platform can induce long-lasting immune responses to multiple SARS-CoV-2 proteins, and potentially elicit a broad-based, cellular and humoral immunity. We decided to explore further the expression of RNAs with our exosome-based delivery system and compare exosomes with lipid nanoparticles specifically focused on short-term toxicity,” said Linda Marbán, PhD, CEO of Capricor. “The data demonstrated functional RNA expression in vivo, further showing the power of our exosome platform to potentially expand into areas beyond SARS-CoV-2. This strengthens my belief that our exosome platform can deliver RNA effectively into cells and drive the expression of functional proteins. The opportunities for pipeline expansion are very exciting, both in vaccines and in the delivery of therapeutic RNAs.”
Login Or Register To Read Full Story